NOTR — BioScience Health Innovations Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for BioScience Health Innovations, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 November 30th | 2022 August 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 3 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-Q | 10-K | 10-K |
Standards: | USG | USG | — | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 1.84 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 1.31 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.008 | 0.026 | 0.029 | 0.083 | 1.76 |
Operating Profit | -0.008 | -0.026 | -0.029 | -0.083 | 0.087 |
Net Income Before Taxes | -0.008 | -0.026 | -0.029 | -0.083 | 0.087 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.008 | -0.026 | -0.029 | -0.083 | 0.087 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.008 | -0.026 | -0.029 | -0.083 | 0.087 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.008 | -0.026 | -0.029 | -0.083 | 0.087 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0.005 | -0.005 | -0.017 | 0.002 |
Dividends per Share |